Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Sandoz launches SurePal growth hormone administration device

Sandoz launches SurePal growth hormone administration device

24th September 2013

Sandoz has announced the launch of SurePal, a new delivery device designed to optimise the administration of its Omnitrope human growth hormone product.

The device utilises cartridges that require no reconstitution or priming and an easy-to-use sliding injection button, as well as safety features such non-interchangeable dose-specific cartridges, a dosage memory function and a concealed needle.

In a usability study conducted among 106 patients in Germany and the US, 92 percent of respondents said they found injection with SurePal to be very easy or easy to accomplish.

The device has received European CE Mark approval and has now been launched in the UK, with a worldwide rollout to follow.

Dr Mark McCamish, Sandoz’s head of global development for biopharmaceuticals and oncology injectables, said: “Sandoz has invested significant time and resources to ensure that SurePal is a simple and secure solution that will provide major benefits to patients.”

The company also announced the introduction of a generic version of Celgene’s myelodysplastic syndrome therapy Vidaza in the US this week.ADNFCR-8000103-ID-801641546-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.